Inactivation of pulmonary surfactant due to serum-inhibited adsorption and reversal by hydrophilic polymers: Experimental

Biophysical Journal

Volumn 89, Issue 3, 2005, Pages 1769-1779

  Taeusch, H William ^a,d   De La Serna, Jorge Bernardino ^b   Perez Gil, Jesus ^b   Alonso, Coralie ^c   Zasadzinski, Joseph A ^c  

^a UNIVERSITY OF CALIFORNIA   (United States)

^b UNIVERSIDAD COMPLUTENSE DE MADRID   (Spain)

^c University of California   (United States)

^d SFGH   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

BERACTANT; CALFACTANT; LUNG SURFACTANT; MACROGOL; PLASMA PROTEIN; POLYMER; PORACTANT;

ADSORPTION; AQUEOUS SOLUTION; ARTICLE; BREWSTER ANGLE MICROSCOPY; CONCENTRATION RESPONSE; IN VIVO STUDY; SERUM; SURFACE PROPERTY; SURFACE TENSION; TEMPERATURE DEPENDENCE;

SUIDAE;

EID: 24144503310     PISSN: 00063495     EISSN: None     Source Type: Journal    
DOI: 10.1529/biophysj.105.062620     Document Type: Article

References (86)

1. Clements, J. A., and M. E. Avery. 1998. Lung surfactant and neonatal respiratory distress syndrome. Am. J. Respir. Crit. Care Med. 157:59-66.
2. Goerke, J. 1998. Pulmonary surfactant: functions and molecular composition. Biochim. Biophys. Acta. 1408:79-89.
3. Notter, R. H. 2000. Lung surfactant: basic science and clinical applications. Marcel Dekker, New York, NY; Basel, Switzerland.
4. Lu, K. W., H. William Taeusch, B. Robertson, J. Goerke, and J. A. Clements. 2000. Polymer-surfactant treatment of meconium-induced acute lung injury. Am. J. Respir. Crit. Care Med. 162:623-628.
5. Tashiro, K., T. Kobayashi, and B. Robertson. 2000. Dextran reduces surfactant inhibition by meconium. Acta Paediatr. 89:1439-1445.
6. Tashiro, K., X. Cui, T. Kobayashi, T. Curstedt, and B. Robertson. 2003. Modified protocols for surfactant therapy in experimental meconium aspiration syndrome. Biol. Neonate. 83:49-56.
7. Hyers, T. M. 1991. Adult respiratory distress syndrome: definition, risk factors and outcome. In Adult Respiratory Distress Syndrome. W. M. Zapol and F. Lemaire, editors. Marcel Dekker, New York, NY. 23-33.
8. Spragg, R. J., and R. M. Smith. 1998. Surfactant replacement in patients with ARDS: result of clinical trials. In Acute Respiratory Distress Syndrome: Cellular and Molecular Mechanisms and Clinical Management. S. Matalon, J. I. Sznajder, and North Atlantic Treaty Organization Scientific Affairs Division, editors. Plenum Press. New York, NY. 107-116.
9. Anzueto, A. 2002. Surfactant supplementation in the lung. Respir. Care Clin. N. Am. 2:211-236.
10. Gregory, T., and K. Steinberg. 1997. Bovine surfactant therapy for patients with acute respiratory distress syndrome. Am. J. Respir. Crit. Care Med. 155:1309-1315.
11. Spragg, R. G. 1991. Abnormalities of lung surfactant function in patients with acute lung injury. In Adult Respiratory Distress Syndrome. W. M. Zapol and F. Lemaire, editors. Marcel Dekker, New York, NY. 381-395.
12. McIntyre, R. C., Jr., E. J. Pulido, D. D. Bensard, B. D. Shames, and E. Abraham. 2000. Thirty years of clinical trials in acute respiratory distress syndrome. Crit. Care Med. 28:3314-3331.
13. Stratton, C., J. Zasadzinski, and D. Elkins. 1988. Lung lamellar body amphiphilic topography: a morphological evaluation using the continuum theory of liquid crystals: I. Anat. Rec. 221:503-519.
14. Zasadzinski, J. A., C. Stratton, and R. Rudolph. 1988. Lung lamellar body amphiphilic topography: a morphological evaluation using the continuum theory of liquid crystals. II. Disclinations, edge dislocations, and irregular defects. Anat. Rec. 221:520-532.
15. Holm, B. A., R. H. Notter, and J. N. Finkelstein. 1985. Surface property changes from interactions of albumin with natural lung surfactant and extracted lung lipids. Chem. Phys. Lipids. 38:287-298.
16. Holm, B. A., L. Keicher, M. Liu, J. Sokolowski, and G. Enhorning. 1991. Inhibition of pulmonary surfactant function by phospholipases. J. Appl. Physiol. 71:317-321.
17. Holm, B. A., G. Enhorning, and R. H. Notter. 1988. A biophysical mechanism by which plasma proteins inhibit lung surfactant activity. Chem. Phys. Lipids. 1988:49-55.
18. Holm, B. A., A. R. Venkitaraman, G. Enhorning, and R. H. Notter. 1990. Biophysical inhibition of synthetic lung surfactants. Chem. Phys. Lipids. 52:243-250.
19. Warriner, H. E., J. Ding, A. J. Waring, and J. A. Zasadzinski. 2002. A concentration-dependent mechanism by which serum albumin inactivates replacement lung surfactants. Biophys. J. 82:835-842.
20. Seeger, W., C. Grube, A. Gunther, and R. Schmidt. 1993. Surfactant inhibition by plasma proteins: differential sensitivity of various surfactant preparations. Eur. Respir. J. 6:971-977.
21. Nakos, G., E. I. Kitsiouli, I. Tsangaris, and M. E. Lekka. 1998. Bronchoalveolar lavage fluid characteristics of early intermediate and late phases of ARDS. Alterations in leukocytes, proteins, PAF and surfactant components. Intensive Care Med. 24:296-303.
22. Mbagwu, N., R. Bruni, J. M. Hernández-Juviel, A. J. Waring, and F. J. Walther. 1999. Sensitivity of synthetic surfactants to albumin inhibition in preterm rabbits. Mol. Genet. Metab. 66:40-48.
23. Ishizaka, A., T. Matsuda, K. Albertine, H. Koh, S. Tasaka, N. Hasegawa, N. Kohno, T. Kotani, H. Morisakai, J. Takeda, M. Nakamura, X. Fang, T. Martin, M. Matthay, and S. Hashimoto. 2004. Elevation of kl-6, a lung epithelial cell marker, in plasma and epithelial lining fluid in ARDS. Am. J. Physiol. Lung Cell. Mol. Physiol. 286:L1088-L1094.
24. Gunther, A., and W. Seeger. 1995. Resistance to surfactant inactivation. In Surfactant Therapy for Lung Disease, Lung Biology in Health and Disease. B. Robertson and H. W. Taeusch, editors. Marcel Dekker, New York, NY. 269-292.
25. Schürch, S., F. Possmayer, S. Cheng, and A. M. Cockshutt. 1992. Pulmonary SP-A enhances adsorption and appears to induce surface sorting of lipid extract surfactant. Am. J. Physiol. 263:L210-L218.
26. Holm, B. A., Z. Wang, and R. H. Notter. 1999. Multiple mechanisms of lung surfactant inhibition. Pediatr. Res. 46:85-93.
27. Hlastala, M., and J. Souders. 2001. Perfluorocarbon enhanced gas exchange: the easy way. Am. J. Respir. Crit. Care Med. 164:1-2.
28. Wang, C., A. Schwan, L. Lairson, J. O'Donnell, G. Byrne, A. Foye, and R. H. Notter. 2003. Surface activity of a synthetic lung surfactant containing a phospholipase resistant phosphonolipid analog of dipalmitoylphosphatidylcholine. Am. J. Physiol. Lung Cell. Mol. Physiol. 285:L550-L559.
29. Cockshutt, A. M., J. Weitz, and F. Possmayer. 1990. Pulmonary surfactant-associated protein A enhances the surface activity of lipid extract surfactant and reverses inhibition by blood proteins in vitro. Biochemistry. 29:8424-8429.
30. Seeger, W., A. Guenther, and C. Thede. 1992. Differential sensitivity to fibrinogen inhibition of sp-c-vs. Sp-b-based surfactants. Am. J. Physiol. 262:L286-L291.
31. Amirkhanian, J. D., and H. W. Taeusch. 1993. Reversible and irreversible inactivation of preformed pulmonary surfactant surface films by changes in subphase constituents. Biochim. Biophys. Acta. 1165:321-326.
32. Amirkhanian, J. D., R. Bruni, A. J. Waring, and H. W. Taeusch. 1991. Inhibition of mixtures of surfactant lipids and synthetic sequences of surfactant proteins sp-b and sp-c. Biochim. Biophys. Acta. 1096:355-360.
33. Rider, E., M. Ikegami, J. A. Whitsett, W. Hull, D. Absolom, and A. H. Jobe. 1993. Treatment responses to surfactants containing natural surfactant proteins in preterm rabbits. Am. Rev. Respir. Dis. 153:669-676.
34. Strayer, D., E. Herting, B. Sun, and B. Robertson. 1996. Antibody to surfactant protein A increases sensitivity of pulmonary surfactant to inactivation by fibrinogen in vivo. Am. Rev. Respir. Dis. 153:1116-1122.
35. Taeusch, H. W., K. W. Lu, J. Goerke, and J. A. Clements. 1999. Hydrophilic polymers added to surfactant enhance treatment of lung injury by reducing surfactant inactivation. Am. J. Respir. Crit. Care Med. 159:A595.
36. Lu, K., H. W. Taeusch, B. Robertson, J. Goerke, and J. A. Clements. 2001. Polyethylene glycol/surfactant mixtures improve lung function after HCl and endotoxin lung injuries. Am. J. Respir. Crit. Care Med. 164:1531-1536.
37. Lu, K., J. Georke, J. A. Clements, and H. W. Taeusch, 2005. Hyaluronan decreases surfactant inactivation in vitro. Pediatr. Res. 57:237-241.
38. Kobayashi, T., K. Ohta, K. Tashiro, K. Nishizuka, W.-M. Chen, S. Ohmura, and K. Yamamoto. 1999. Dextran restores albumin-inhibited surface activity of pulmonary surfactant extract. J. Appl. Physiol. 86:1778-1784.
39. Kobayashi, T., K. Tashiro, X. Cui, T. Konzaki, Y. Xu, C. Kabata, and K. Yamamoto. 2001. Experimental models of acute respiratory distress syndrome: clinical relevance and response to surfactant therapy. Biol. Neonate. 80:26-28.
40. Lu, J. J., W. W. Y. Cheung, L. M. Y. Yu, Z. Policova, D. Li, M. L. Hair, and A. W. Neumann. 2002. The effect of dextran to restore the activity of pulmonary surfactant inhibited by albumin. Respir. Physiol. Neurobiol. 130:169-179.
41. Cui, X., K. Tashiro, H. Matsumoto, Y. Tsubokawa, and T. Kobayashi. 2003. Aerosolized surfactant and dextran for experimental acute respiratory distress syndrome caused by acidified milk in rats. Acta Anaesthesiol. Scand. 47:853-860.
42. Yu, L. M. Y., J. J. Lu, I. W. Y. Chiu, K. S. Leung, Y. W. Chan, L. Zhang, Z. Policova, M. L. Hair, and A. W. Neumann. 2004. Polyethylene glycol enhances the surface activity of a pulmonary surfactant. Colloids Surf. B Biointerfaces. 36:167-176.
43. Diemel, R. V., H. P. Haagsman, and G. Putz. 2002. In vitro and in vivo intrapulmonary distribution of fluorescently labelled surfactant. Crit. Care Med. 30:1083-1090.
44. Krishnan, A., J. Sturgeon, C. A. Siedlecki, and E. A. Vogler. 2003. Scaled interfacial activity of proteins at the liquid-vapor interface. J. Biomed. Mater. Res. 68A:544-557.
45. Zasadzinski, J. A., T. F. Alig, and C. Alonso, J. Bernadino de la Serna, J. Perez-Gil, and H.W. Taeusch. 2005. Inhibition of pulmonary surfactant adsorption by serum and the mechanisms of reversal by hydrophilic polymers. Part 2. Theory. Biophys. J. 89:1621-1629.
46. Schürch, S., F. H. Y. Green, and H. Bachofen. 1998. Formation and structure of surface films: captive bubble surfactometry. Biochim. Biophys. Acta. 1408:180-202.
47. Alig, T. F., H. E. Warriner, L. Lee, and J. A. Zasadzinski. 2004. Electrostatic barrier to recovery of dipalmitoylphosphatidylglycerol monolayers after collapse. Biophys. J. 86:897-904.
48. Kaplan, P. D., J. L. Rourke, A. G. Yodh, and D. J. Pine. 1994. Entropically driven surface phase separation in binary colloidal mixtures. Phys. Rev. Lett. 72:582-585.
49. Dinsmore, A. D., D. T. Wong, P. Nelson, and A. G. Yodh. 1998. Hard spheres in vesicles: curvature-induced forces and particle induced curvature. Phys. Rev. Lett. 80:409-412.
50. Dinsmore, A. D., A. G. Yodh, and D. J. Pine. 1996. Entropic control of particle motion using passive surface microstructures. Nature. 383:239-242.
51. Mondain-Monval, O., F. Leal-Calderon, J. Phillip, and J. Bibette. 1995. Depletion forces in the presence of electrostatic double layer repulsion. Phys. Rev. Lett. 75:3364-3367.
52. Bickel, T. 2003. Depletion forces near a soft interface. J. Chem. Phys. 118:8960-8968.
53. Dehority, W., K. W. Lu, and H. W. Taeusch. 2001. Increased lung water may affect responses to treatment of acute lung injury in rats with polymer-surfactant mixtures. Am. J. Respir. Crit. Care Med. 163:A81.
54. Dehority, W., K. W. Lu, J. A. Clements, J. Goerke, and H. W. Taeusch. 2005. Polymer-surfactant therapy for adult rats with acute lung injury induced by saline lavage. Pediatr. Res. In press.
55. Rouser, G., G. Siakotos, and A. Fleischer. 1966. Quantitative analysis of phospholipids by thin layer chromatography and phosphorous analysis of spots. Lipids. 1:85-86.
56. Bligh, E., and W. Dyer. 1959. A rapid method of total lipid extraction and purification. Can. J. Biochem. Physiol. 37:911-917.
57. Lu, K. W., H. W. Taeusch, J. Goerke, and J. A. Clements. 1999. Hydrophilic polymers prevent surfactant inactivation. J. Invest. Med. 47:32A.
58. Ding, J., D. Y. Takamoto, A. Von Nahmen, M. M. Lipp, K. Y. C. Lee, A. J. Waring, and J. A. Zasadzinski. 2001. Effects of lung surfactant proteins, sp-b and sp-c, and palmitic acid on monolayer stability. Biophys. J. 80:2262-2272.
59. Ding, J., I. Doudevski, H. Warriner, T. Alig, J. Zasadzinski, A. J. Waring, and M. A. Sherman. 2003. Nanostructure changes in lung surfactant monolayers induced by interactions between popg and sp-b. Langmuir. 19:1539-1550.
60. Warriner, H. E., A. T. Ngo, J. A. Zasadzinski, and J. Ding. 2005. Nanostructure and dynamics of biocompatible surfactant monolayers and bilayers. In Handbook of Nanostructured Biomaterials and their Applications in Nanobiotechnology, Chapter K. H. S. Nalwa, editor. American Scientific Publishers, New York, NY.
61. Bernhard, W., J. Mottaghian, A. Gebert, G. A. Rau, H. von der Hardt, and C. F. Poets. 2000. Commercial versus native surfactants. Am. J. Respir. Crit. Care Med. 162:1524-1533.
62. Braun, A. 2004. Microstructure and properties of a lipid-based drug delivery system and lung surfactant suspensions. Masters thesis. Department of Chemical Engineering, University of California, Santa Barbara, CA.
63. Ding, J. Q., H. E. Warriner, and J. A. Zasadzinski. 2002. Viscosity of two-dimensional suspensions. Phys. Rev. Lett. 88:168102.
64. Bringezu, F., J. Q. Ding, G. Brezesinski, and J. A. Zasadzinski. 2001. Changes in model lung surfactant monolayers induced by palmitic acid. Langmuir. 17:4641-4648.
65. Lee, K. Y. C., A. Gopal, A. Von Nahmen, J. A. Zasadzinski, J. Majewski, G. S. Smith, P. B. Howes, and K. Kjaer. 2002. Influence of palmitic acid and hexadecanol on the phase transition temperature and molecular packing, of dipalmitoylphophatidyl-choline monolayers at the air-water interface. J. Chem. Phys. 116:774-783.
66. Alonso, C., and J. Zasadzinski. 2004. Linear dependence of surface drag on surface viscosity. Physical Review E 69:021602-021601-021606.
67. Israelachvili, J. N. 1992. Intermolecular and Surface Forces. Academic Press, London, UK.
68. Stone, H. A. 1995. Fluid motion of monomolecular films in a channel flow geometry. Phys. Fluids. 2931-2937.
69. Stratton, C. J. 1977. The periodicity and architecture of lipid retained and extracted lung surfactant and its origin from multilamellar bodies. Tissue Cell. 9:301-316.
70. Zasadzinski, J., C. Stratton, and D. Heetderks. 1987. Liquid crystal morphology and defects in in vivo human and mammalian phosphatidylcholine lung multilamellar surfactant. Langmuir. 3:592-595.
71. Perez-Gil, J. 2002. Molecular interactions in pulmonary surfactant films. Biol. Neonate. 81:6-15.
72. Winsel, K., D. Honig, K. Lunkenheimer, K. Geggel, and C. Witt. 2003. Quantitative Brewster angle microscopy of the surface film of human broncho-alveolar lavage fluid. Eur. Biophys. J. 32:544-552.
73. Bruni, R., B. R. Fan, R. Davie-Cu, H. W. Taeusch, and F. J. Walther. 1996. Inactivation of surfactant in rat lungs. Pediatr. Res. 39:236-240.
74. Lu, K., J. Georke, J. A. Clements, and H. W. Taeusch. 2005. Hyaluronan reduces surfactant inhibition and improves rat lung function after meconium lung injury. Pediatr. Res. (Epub ahead of print).
75. Sahu, S., A. Tanswell, and W. Lynn. 1980. Isolation and characterization of glycosaminoglycans secreted by human foetal lung type II pneumonocytes in culture. J. Cell Sci. 42:183-188.
76. Skinner, S., M. Post, J. Torday, A. Stiles, and B. Smith. 1987. Characterization of proteoglycans synthesized by fetal rat lung type ii pneumonocytes in vitro and the effects of cortisol. Exp. Lung Res. 12:253-264.
77. Stratton, C., W. Douglas, and J. McAteer. 1978. The surfactant system of human fetal lung organotypic cultures: ultrastructural preservation by a lipid-carbohydrate retention method. Anat. Rec. 192:481-492.
78. Scarpelli, E. M., B. Clutario, and F. Taylor. 1967. Preliminary identification of the lung surfactant system. J. Appl. Physiol. 23:880-887.
79. Nir, I., and D. Pease. 1976. Polysaccharides in lung alveoli. Am. J. Anat. 147:457-458.
80. Bray, B. A. 2001. The role of hyaluronan in the pulmonary alveolus. J. Theor. Biol. 210:121-130.
81. Cantor, J., B. Shteyngart, J. Cerreta, M. Liu, G. Armand, and G. Turino. 2000. The effect of hyaluronan on elastic fiber injury in vitro and elastase-induced airspace enlargement in vivo. Proc. Soc. Exp. Biol. Med. 225:65-71.
82. Turino, G., and J. Cantor. 2003. Hyaluronan in respiratory injury and repair. Am. J. Respir. Crit. Care Med. 167:1169-1175.
83. Lu, J. J., L. M. Y. Yu, W. W. Y. Cheung, Z. Policova, D. Li, M. L. Hair, and A. W. Neumann. 2003. The effect of concentration on the bulk adsorption of bovine lipid extract surfactant. Colloids Surf. B. 29:119-130.
84. Tchoreloff, P., B. Denizot, J. Proust, A. Gulik, and F. Puisieux. 1989. Structural and physicochemical study of natural pulmonary surfactant and synthetic phospholipids spread on a liquid/air interface. Congr. Int. Technol. Pharm. 3:41-50.
85. Tchoreloff, P., A. Gulik, B. Denizot, J. E. Proust, and F. Puisieux. 1991. A structural study of interfacial phospholipid and lung surfactant layers by transmission electron microscopy after Blodgett sampling: influence of surface pressure and temperature. Chem. Phys. Lipids. 59:151-165.
86. Ikegami, M., B. M. Elhalwagi, N. Palaniyar, K. Dienger, T. Korfhagen, J. A. Whitsett, and F. X. McCormack. 2001. The collagen-like region of surfactant protein A (SP-A) is required for correction of structural and functional defects in the SP-A null mouse. J. Biol. Chem. 276:38542-38548.